Final Program - Korese · MediGuideTM Technology is the ˜rst and only solution that enables physicians to navigate devices ... Thorsten Lewalter 12:00 – 12:15 Case ... Alter ab

Program Chairs

Thorsten Lewalter, MD, PhD

Isar Heart Center, Munich

University of Bonn, Bonn, Germany

Sanjeev Saksena, MD

Rutgers Robert Wood Johnson Medical School,

Piscataway, NJ, USA

The Electrophysiology Research Foundation,

Warren, NJ, USA

+ + + + + + + + + + + + + + + + + + + + + + + + + + Final Program

+ + + + + + + + + + + + + + + + + + + + + + + + + + www.isie-symposium.com

Unless otherwise noted, TM indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICALand the nine-squares symbol are registered and unregistered trade marks and service marks of St. J ude Medical, Inc. and its related companies.©2013 St. Jude Medical, Inc. All rights reserved.

www.sjmprofessional.com

From Live X-rayNavigating Away

MediGuide™ Technology

MediGuide TM Technology is the �rst and only solution that enables physicians to navigate deviceson pre-recorded X-ray images which allows the physician to reduce the duration of live X-rayduring a procedure. MediGuide TM Technology applies 3D visualization and precise navigationto pre-recorded 2D X-ray images, which can be used by the physician to perform complex electrophysiology procedures and CRT implants.

PROVIDINGDIRECTION

Welcome Address

Dear Colleagues,

We are very pleased to welcoming you to the

Seventh International Symposium for Interventional

Electrophysiology in Munich, Germany, September

18–20, 2013. This meeting is being organised by the

Isar Heart Center and the Electrophysiology Research

Foundation in New Jersey.

The symposium will maintain its focus on new

technologies, innovative therapy, and new scientific

directions in research in the management of cardiac

arrhythmias. We are certain that this will be an important

and stimulating educational event. The proceedings of

the symposium will be published in a special issue of

the Journal of Interventional Electrophysiology.

We hope you will join the symposium and are looking

forward to meet you at the meeting.

With warm personal regards,

Thorsten Lewalter, MD, PhD Sanjeev Saksena, MD

�

�

Wednesday, September 18

� Featured Workshops complemented

by case studies and live cases

Objective: Designed to showcase new

drugs, technologies and/or teach new

antiarrhythmic therapy, complex or new

procedures in cardiac rhythm manage-

ment and cardiology

Cardiovascular and Electrophysiology

Fellows Course

Thursday, September 19

Didactic lectures and interactive

discussions

Objectives: New directions in basic sci-

ence and technology with therapeutic

impact: Trends in current therapy for the

practicing cardiologist and EP

Sessions: I, II, III, IV

• Basic science and Pharmacology

• New Technology

_ Atrial Fibrillation: Pharmacology

and Clinical trials of Anticaogulants

_ Pacing & ICD Therapy: New techno-

logy (wireless devices and MRI safe

devices and leads, applications of

remote monitoring, current Regis-

tries and clinical trials) Ventricular

Fibrillation and Sudden Death

Friday, September 20

Objectives: Integrating advances in

basic science and technology into an

evidence based world

Sessions: V, VI, VII

• Catheter ablation: clinical trials

Heart failure clinical trials

• Outcomes and Clinical Trials in

Electrophysiology and Pacing

Overall structure and Objectives

of Program

Focus on advances in basic science and

technology, evolving new techniques

and therapies in an evidence

based world of medicine

PROGRAM | DAY 1

Wednesday, September 18

�

Workshop 1:

Imaging, Mapping and Navigation in the EP Lab – New Techniques and How to

Apply Them (An Interactive faculty-audience workshop)

8:00 – 10:30 Co Chairs: Alexander Leber /

Balbir Singh

8:00 – 8:20 Intracardiac Echocardio-

graphy: How to perform ICE

guided CRT & LAA imaging

from new imaging windows

Sanjeev Saksena

8:20 – 8:40 Cardiac MRI and Cardiac

CT: How to integrate into

the EP Lab

Klaus Tiemann

8:40 – 9:00 Case Demonstration: Role

of �D TEE to guide inter-

ventional procedures

Klaus Tiemann

9:00 – 9:20 Case Demonstration: CT

reconstruction of LAA

morphologies

Andrea Natale

9:20 – 9:40 Case Demonstration: How

to perform rotor mapping –

the TOPERA technique:

Sanjiv Narayan

9:40 – 10:00 Case Demonstration: High-

density mapping of Atrial

tachycardia–the RHYTHMIA

experience

Josef Kautzner

10:00 – 10:20 Mapping and Ablation of

VF: How and For Whom

Stephan Willems

10:30 – 11:00 Coffee Break

PROGRAM | DAY 1 Wednesday, September 18

11:00 – 12:30 Co-Chairs: Johannes Brach-

mann / Sanjeev Saksena

11:00 – 11:20 New techniques for

Robotic Navigation in AF

Andrea Natale

11:20 – 11:40 Robotic Navigation with

the Hansen system:

Learning curves and

lessons learned

Werner Jung

11:40 – 12:00 Case Demonstration:

AF Ablation using Stereo-

taxis magnetic robotic

navigation system

Georg Nölker


The “Mediguide” Mapping

& Ablation Experience

Gerhard Hindricks


Catheter Ablation using

the Amigo Robotic Naviga-

tion system using an open

architecture ablation

catheter concept

Leif-Hendrik Boldt

12:30 – 13:30 Lunch

�

8:00 – 10:00 Co-Chairs: Eckhard Alt /

Dobromir Dobrev

8:00 – 8:30 Dronedarone: guideline

position and current

clinical use

Andreas Goette

8:30 – 9:00 New Targets for Antiar-

rhythmic Drug Therapy:

Atrial specific agents and

substrate modifiers

Dobromir Dobrev

9:00 – 9:30 MicroRNA and atrial fibril-

lation: biomarker or thera-

peutic target?

Reza Wakili

9:30 – 10:00 Fundamentals of cardiac

regeneration and repair

Eckhard Alt



Workshop 2:

New Directions in Antiarrhythmic Therapy

and Stroke Prevention

10:30 – 12:30 Co-Chairs: Michael

Ezekowitz / Ernst Vester

10:30 – 11:00 Second Generation NOACs:

Pharmacology and Clinical

Trials

Michael Ezekowitz

11:00 – 11:20 Cardioversion of Atrial

Fibrillation: Is Dabigatran

preferable to Warfarin –

The RE-LY Experience:

Rangadham Nagarakanti

11:20 – 11:45 Factor X inhibitors

Rivaroxaban and Apixa-

ban: Clinical trials and

application

Ernst Vester

11:45 – 12:00 Clinical Indication for

left atrial appendage

occlusion

Thorsten Lewalter


Amplatzer device

implantation

Thorsten Lewalter

12:15 – 12:30 Panel Discussion

12:30 – 13:30 Lunch

8

13:30 – 16:45 Co-Chairs: Andrea Natale /

Gerhard Hindricks

13:30 – 14:00 “State of the Art lecture”:

Established and Upcom-

ing Technology for PV

Disconnection

Andrea Natale


Cryo Balloon Technology

Uwe Dorwarth


Endoscopic Laser Balloon

Ablation

Thorsten Lewalter




Substrate Identification

and Ablation Strategy in

persistent AF

Michel Haissaguerre


Ablation of Human AF

Rotors

Sanjiv Narayan


Ablation of CFAE’s

Isabell Deisenhofer


Hybrid therapy for AF

treatment

Sanjeev Saksena


16:45 – 18:00 Co-Chairs: Raj Kaushik /

Thorsten Hanke


Ablation in persistent AF –

the surgeons perspective

Nico Doll


Endoscopic Surgical AF

Ablation as part of a

hybrid strategy

Stephen Wildhirt


Stand alone surgical AF

ablation

Nico Doll


Relevance of continous

AF monitoring

Thorsten Hanke

18:00 Wrap-Up


Workshop �:

Advanced Catheter Ablation in AF and VT/VF –

New Technologies and Intervention Targets

9

13:30 – 14:45 Co-Chairs: Gerhard Stein-

beck / Sanjeev Saksena

13:30 – 14:00 Renal Denervation –

New Tools and new

applications

Thomas Schmitz


The EnligHTN dener-

vation system

Thomas Schmitz

14:15 – 14:30 Lead Extraction

Raj Kaushik

14:30 – 14:45 Practical Experience with

MRI Safe Devices:

Werner Jung


15:15 – 17:00 Co-Chairs: Kamal Sethi /

Andreas Goette

15:15 – 15:45 Clinical Experience with

Subcutaneous defibrillator

Riccardo Cappato

15:45 – 16:10 Wireless Telemetry and

Remote Monitoring of

ICDs/CRT’s: Practical

implementation and envi-

ronmental interactions:

Stefan Sack

16:10 – 16:30 Bridge therapy in Defibril-

lation – Increasing role of

the LIFEVEST concept

Helmut Klein


Subcutaneous ICD

implantation

Riccardo Cappato


Intraoperative Optimiza-

tion of CRT with ICE

Sanjeev Saksena


and Wrap-Up


Workshop �:

New Devices for Rhythm Monitoring, Bradycardia,

Heart Failure and Hypertension

L.D

E.G

M.0

1.20

13.0

973

www.xarelto.de

„ Kann man Schlaganfall-Prophylaxe bei Vorhoffl immerndeutlich vereinfachen?“

Fortschritt von Bayer.

1 x 1 täglich

Xarelto 15 mg / 20 mg FilmtablettenWirkstoff: Rivaroxaban. Vor Verschreibung Fachinformation beachten. Zusammensetzung: Wirkstoff: 15 mg / 20 mg Rivaroxaban. Sonstige Bestandteile:Mikrokristalline Cellulose, Croscarmellose-Natrium, Lactose-Monohydrat, Hypromellose, Natriumdodecylsulfat, Magnesiumstearat, Macrogol (3350), Titan-oxid (E171), Eisen(III)oxid (E172). Anwendungsgebiete: Prophylaxe von Schlaganfällen und systemischen Embolien bei erwachsenen Patienten mit nicht-valvulärem Vorhoffl immern und einem oder mehreren Risikofaktoren, wie kongestiver Herzinsuffi zienz, Hypertonie, Alter ab 75 Jahren, Diabetes mellitus, Schlaganfall oder transitorischer ischämischer Attacke in der Anamnese. Behandlung von tiefen Venenthrombosen (TVT) und Lungenembolien (LE) sowie Prophylaxe von rezidivierenden TVT und LE bei Erwachsenen. Gegenanzeigen: Überempfi ndlichkeit gegen Rivaroxaban oder einen d. sonst. Bestandteile; klinisch relevante akute Blutungen; Läsionen oder Situationen mit einem signifi kanten Risiko einer schweren Blutung; gleichzeitige Anwendung von anderen Antikoagulanzien außer bei der Umstellung der Antikoagulationstherapie auf oder von Rivaroxaban oder wenn unfrakt. Heparin in Dosen gegeben wird, die notwendig sind, um die Durchgängigkeit eines zentralvenösen oder arteriellen Katheters zu erhalten; Lebererkrankungen, die mit einer Koagulopathie u. einem klinisch relevanten Blutungsrisiko, einschließlich zirrhotischer Patienten mit Child Pugh B und C, verbunden sind; Schwangerschaft u. Stillzeit. Vorsichtsmaß-nahmen und Warnhinweise: Eine klinische Überwachung in Übereinstimmung mit der antikoagulatorischen Praxis wird während der gesamten Behand-lungsdauer empfohlen. Die Gabe von Xarelto sollte bei Auftreten einer schweren Blutung unterbrochen werden. Die Anwendung von Rivaroxaban wird nicht empfohlen bei Patienten: - mit einer schweren Nierenfunktionseinschränkung (Kreatinin-Clearance < 15 ml/min), - die zeitgleich eine systemische Behand-lung mit Wirkstoffen, die gleichzeitig stark CYP3A4 und P-gp inhibieren, z. B. Azol-Antimykotika oder HIV-Proteaseinhibitoren, erhalten, - mit einem erhöhten Blutungsrisiko und, da keine Daten vorliegen, bei Patienten: - unter 18 Jahren, - mit künstlichen Herzklappen, - mit einer LE, die hämodynamisch instabil sind oder eine Thrombolyse oder pulmonale Embolektomie benötigen, - die zeitgleich mit Dronedaron behandelt werden. Die Anwendung sollte mit Vorsicht erfolgen bei Patienten: - mit erhöhtem Blutungsrisiko, - mit einer schweren Nierenfunktionsstörung (Kreatinin-Clearance 15 - 29 ml/min), - mit einer Nieren-funktionsstörung, wenn gleichzeitig andere Arzneimittel eingenommen werden, die zu erhöhten Rivaroxaban Plasmaspiegeln führen, - die gleichzeitig auf die Gerinnung wirkende Arzneimittel erhalten, - die gleichzeitig starke CYP3A4 Induktoren erhalten. Bei Patienten mit dem Risiko einer ulzerativen gastrointestinalen Erkrankung kann eine prophylaktische Behandlung erwogen werden. Obwohl die Behandlung mit Rivaroxaban keine Routineüberwa-chung der Exposition erfordert, können die mit einem kalibrierten quantitativen Anti-Faktor Xa-Test bestimmten Rivaroxaban-Spiegel in Ausnahmesitu-ationen hilfreich sein. Für Patienten mit einer mittelschweren oder schweren Nierenfunktionsstörung sowie für Patienten mit einer TVT/LE, deren abgeschätztes Blutungsrisiko überwiegt, gelten spezielle Dosisempfehlungen. Xarelto enthält Lactose. Nebenwirkungen: Häufi g: Anämie, Schwindel, Kopfschmerzen, Augeneinblutungen, Hypotonie,Hämatome, Epistaxis, Hämoptyse, Zahnfl eischbluten, gastrointestinale Blutungen, gastrointestinale u. abdominale Schmerzen, Dyspepsie, Übelkeit, Verstopfung, Durchfall, Erbrechen, Pruritus, Hautrötung, Ekchymose, kutane und subkutane Blutung, Schmerzen in den Extremitäten, Blutungen im Urogenitaltrakt, Nierenfunktionseinschränkung, Fieber, periphere Ödeme, verminderte Leistungsfähigkeit, Transaminasenanstieg, postope-rative Blutungen,Bluterguss, Wundsekretion. Gelegentlich: Thrombozythämie, allergische Reaktion, allergische Dermatitis, zerebrale und intrakranielle Blutungen, Synkope, Tachykardie, trockener Mund, Leberfunktionsstörung, Urtikaria, Hämarthros, Unwohlsein, Anstieg von: Bilirubin, alkalischer Phospha-tase im Blut, LDH, Lipase, Amylase, GGT. Selten: Gelbsucht, Blutung in einen Muskel, lokale Ödeme, Anstieg von konjugiertem Bilirubin, vaskuläres Pseudo-aneurysma (gelegentlich beobachtet bei der Präventionstherapie nach einem ACS nach perkutaner Intervention). Häufi gkeit nicht bekannt: Kompartment-syndrom oder (akutes) Nierenversagen als Folge einer Blutung. Verschreibungspfl ichtig. Stand: DE/3; 08/2013 Bayer Pharma AG, 13342 Berlin, Deutschland

130730_01_AZ_VHF_7th_Symp_Electrophysiology.indd 1 30.07.13 16:11

PROGRAM | DAY 2

Thursday, September 19

12

8:00 – 8:15 Welcome

Thorsten Lewalter /

Sanjeev Saksena

8:15 – 9:00 Opening Plenary Session

Interventional EP: Past,

Present and Future

Co-Chairs: John Camm /

Gerald Naccarelli

8:15 – 8:45 Introduction:

Symposium on Interven-

tional Electrophysiology:

Thorsten Lewalter /

Berndt Lüderitz

8:45 – 9:15 Keynote Lecture:

Thromboembolic risk

in Interventional Electro-

physiology Practice:

Recent Advances in Diag-

nosis and Management

Michael Ezekowitz

9:15 – 10:30 Session I:

Advances in Basic Sci-

ence and Regenerative

Medicine

Co-Chairs: Stefan Kääb /

Dobromir Dobrev

9:15 – 9:45 Genetics in AF – Current

Understanding

Arne Pfeufer

9:45 – 10:15 Stem Cell Therapy for

Heart Disease: Current

Clinical Status

Martin Bergmann



11:00 – 13:00 Session II:

New Technologies in

Catheter Ablation

Co-Chairs: Sanjeev Saksena/

Stephan Willems

11:00 – 11:30 Mediguide – Impact

on Catheter Ablation

Techniques and Workflow

Dhanunjay Lakireddy

11:30 – 12:00 Stereotactic and Robotic

Systems for Catheter

Manipulation

Georg Nölker

12:00 – 12:30 Endoscopic Ablation

Systems

Thorsten Lewalter

PROGRAM | DAY 2 Thursday, September 19

1�

PROGRAM | DAY 2 Thursday, September 19

12:30 – 13:00 Contact force measure-

ment – the final missing

link in catheter ablation?

Claudia Herrera-Siklody

13:00 – 14:00 Lunch

14:00 – 15:50 Session III:

Atrial Fibrillation: Pharma-

cology and Clinical trials

of Anticaogulants

Co-Chairs: Gerhard

Steinbeck / Franz Goss

14:00 – 14:20 Clinical Trials with Atrial

Specific Agents

Dobromir Dobrev

14:20 – 14:40 RAAS Inhibitors and Fish

Oils: Do They Have a Role

in Preventing AF?

Gerald Naccarelli

14:40 – 15:00 Newer antithrombotics

and their antidotes:

current status

Sam Lévy

15:00 – 15:30 Keynote Lecture:

Guidelines for antiarrhyth-

mic and anticoagulant

therapy: Trial evidence

versus Post marketing

Surveillance

A. John Camm



16:15-18:00 Session IV:

Pacing and Defibrillation

Co-Chairs: Sanjeev Saksena/

Berndt Lüderitz

16:15 – 17:10 Left ventricular or biven-

tricular pacing? Single or

multielectrode leads?

An implanter’s viewpoint

Kamal Sethi

17:10 – 17:30 ICE guided cardiac resyn-

chronization therapy and

the CHOICE trial

April Slee

17:30 – 17:50 Subcutaneous defibrilla-

tor: clinical evidence and

current practice

Riccardo Cappato

17:50 – 18:10 Reverse remodeling of the

left atrium with dual site

right atrial pacing

Randy Nagarakanti


I’m the only babysitter they trust.

[I WEAR IT BECAUSE...]

LifeVest median daily use is 94% or 22.6 hours per day1

Prescribe it to protect her from sudden cardiac arrest.She will wear it for so many other reasons.

20C0162revFI

+49 (0)2236 878755 | www.zoll.lifecor.com

©2012 ZOLL Medical Corporation. All rights reserved. ZOLL andLifeVest are trademarks and/or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries.

1 ZOLL. Patient Use, Indications, and Coverage. February 2012. Availableat http://www.lifevest.zoll.com/medical-professionals/patientuse.asp,Accessed February 28, 2012.

The Journal of Innovations inCardiac Rhythm Management, March 2012: 1-2.

• Patients feel more confident returning to their normal daily activities when wearing the LifeVest2

• LifeVest patients don’t worry as much because they know the LifeVest is

protecting them2

2

PROGRAM | DAY �

Friday, September 20

1�

8:00 – 9:45 Session V:

Catheter ablation and

Treatment strategies in VT

and Atrial Fibrillation:

clinical trials

Co-Chairs: Gerald Nacca-

relli / Riccardo Cappato

8:00 – 8:20 Concepts and Current Trial

Status of VT ablation in

Structural Heart Disease

Balbir Singh

8:20 – 8:40 Dronedarone – Trial

status and perspective

Gerald Naccarelli

8:40 – 9:00 FREEZE and Fire&ICE:

Is the Cryo-Ballon “hot”?

Ellen Hoffmann

9:00 – 9:20 Is Mortality the key out-

come for AF therapy trials?

Sanjeev Saksena

9:20 – 9:40 Cryptogenic Stroke – The

CRYSTAL AF Study

Johannes Brachmann

9:40 – 11:00 Session VI:

Heart failure clinical trials

Co-Chairs: Ellen Hoffmann /

Kamal Sethi

9:40 – 10:00 Remote Heart Failure

Monitoring in Device

Patients

Stefan Sack

10:00 – 10:20 New Sensor Technology

for HF in Clinical Trials

Werner Jung

PROGRAM | DAY � Friday, September 20

10:20 – 11:00 CASTLE-AF: Is there an

AF-HF dialogue?

Johannes Brachmann



11:15 – 13:00 Session VII:

Outcomes and

Clinical Trials

Co-Chairs: Thorsten Le-

walter / Sanjeev Saksena

11:15 – 11:45 Key Note Lecture: History

of Oral Anticoagulation

Berndt Lüderitz

11:45 – 12:05 ICD Lead registries and

prospective clinical trials:

the view in 201�

Dhanunjay Lakireddy

12:05 – 12:25 Sillent stroke in catheter

ablation procedures:

outcomes and clinical

trials

Thomas Deneke

12:25 – 12:55 Periprocedural anticoagu-

lation with dabigatran,

rivaroxaban and apixaban

Sam Lévy

12:55 – 13:15 Clinical Outcome in AF

Ablation: Results from a

Prospective Real World

Registry

Jochen Senges

13:15 – 13:30 Closing Remarks

Sanjeev Saksena

13:30 – 15:00 Farewell Buffet

1�

Course Directors

Thorsten Lewalter, MD, PhD

Isar Heart Center, Munich

University of Bonn, Bonn, Germany

Sanjeev Saksena, MD

Rutgers Robert Wood Johnson Medical

School, Piscataway, NJ, USA

The Electrophysiology Research

Foundation, Warren, NJ, USA

International Faculty

Martin Bergmann, Hamburg, DE

Leif-Hendrik Boldt, Berlin, DE

Johannes Brachmann, Coburg, DE

A. John Camm, London, GB

Riccardo Cappato, Milan, IT

Isabell Deisenhofer, Munich, DE

Thomas Deneke, Bad Neustadt, DE

Dobromir Dobrev, Essen, DE

Uwe Dorwarth, Munich, DE

Nico Doll, Stuttgart, DE

Michael Ezekowitz, Wynnewood, PA, US

Andreas Goette, Paderborn, DE

Franz Goss, Munich, DE

Michel Haissaguerre, Bordeaux, FR

Thorsten Hanke, Lübeck, DE

Claudia Herrera-Siklody, Ludwigsburg, DE

Gerhard Hindricks, Leipzig, DE

Ellen Hoffman, Munich, DE

Werner Jung, Villingen, DE

Stefan Kääb, Munich, DE

Josef Kautzner, Prague, CZ

Raj Kaushik, Passaic, NJ, US

Helmut Klein, Munich, DE

Dhanunjay Lakireddy, Kansas City, KS, US

Alexander Leber, Munich, DE

Sam Lévy, Marseille, FR

Thorsten Lewalter, Munich, DE

Berndt Lüderitz, Bonn, DE

Gerald Naccarelli, Hershey, PA, US

Randy Nagarakanti, New Orleans, LA, US

Sanjiv Narayan, San Diego, CA, US

Andrea Natale, Austin, TX, US

Georg Nölker, Bad Oeynhausen, DE

Arne Pfeufer, Munich, DE

Stefan Sack, Munich, DE

Sanjeev Saksena, New Brunswick, NJ, US

Thomas Schmitz, Essen, DE

Jochen Senges, Ludwigshafen, DE

Kamal Sethi, New Delhi, IN

Balbir Singh, New Delhi, IN

April Slee, MS, Warren, NJ, US

Gerhard Steinbeck, Munich, DE

Klaus Tiemann, Munich, DE

Ernst Vester, Duesseldorf, DE

Reza Wakili, Munich, DE

Stephen Wildhirt, Munich, DE

Stephan Willems, Hamburg, DE

18

Organized by

Isar Heart Center,

Munich / Germany

The Electrophysiology

Research Foundation,

Warren / NJ, USA

Endorsed by

The German Cardiac Society

Bundesverband Niedergelassener

Kardiologen e. V. (BNK)

For additional information

contact program coordinators:

Paula Cardona (United States)

Phone: 001-732-302-9990

Fax: 001-732-302-9911

Email: [email protected]

Daniela Lutz (Europe)

Phone: +49.89.14990360-00

Fax: +49.89.14990360-10


German Cardiac Society

BAYERISCHELANDESÄRZTEKAMMERKörperschaft des öffentlichen Rechts

Platinum Sponsor

Gold Sponsors

Silver Sponsors

Bronze Sponsors

3.000,- EUR

BIOTRONIK

19

Hotelreservation for

Hilton Munich Park by

KORESE

Convention & Event Service GmbH

Jochen Geiger

Kornhausgasse 4

88212 Ravensburg • Germany

Phone: +49.751 56053-0

Fax: +49.751 56053-18


Website: www.korese.com

Symposium Information

Venue:

Hilton Munich Park Hotel

Am Tucherpark 7

80538 München

Germany

Date:

September 18–20, 2013

Official language:

English

Accreditation:

The symposium is accredited by the

‘Bayerische Landesaerztekammer’.

Registration and accomodation:

Could be made via the electronic form

placed on the symposium

website www.isie-symposium.com

Days Fellows Regular

Day 1 50,- € 75,- €

Day 2+3 75,- € 90,- €

All Days 90,- € 125,- €

Registration fees:

+ + + + + + + + + + + + + + + + + + + + + + + + + + www.isie-symposium.com

Documents

Final Program - Korese · MediGuideTM Technology is the ˜rst and only solution that enables physicians to navigate devices ... Thorsten Lewalter 12:00 – 12:15 Case ... Alter ab